Michael Birrer on Predicting Outcomes in Ovarian Cancer

Video

Michael Birrer, MD, PhD, Harvard Medical School, discusses what he hopes to discover as factors that influence long-term survival in patients and survivors with ovarian cancer.

Michael Birrer, MD, PhD, Harvard Medical School, discusses what he hopes to discover as factors that may influence long-term survival in patients and survivors of ovarian cancer.

Birrer is involved in a study examining psychosocial, quality of life, and genomic factors at diagnosis that correlate with survival lasting longer than 10 years. Hopefully, he says, this will lead to more personalized medicine so that every patient with ovarian cancer can become a long-term survivor.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
2 experts are featured in this series.
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Related Content
Image of patients of different ages in a waiting room

Risk Factors Determine Symptom Burden Profiles by Age Group

Bridget Hoyt
April 18th 2025
Article

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Photo of a woman with her hand on her forehead in stress

Opinion: Crowdfunding Falls Short in Gynecologic Cancer

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
Published: April 14th 2025 | Updated: April 16th 2025
Article

Oncology nurses can support patients facing financial toxicity by offering guidance on available resources and providing emotional support.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Simple line illustration of the female reproductive system with a tumor on the uterine lining, on a light blue background

Pembrolizumab Shows ORR, Tolerability in Previously Treated Gynecologic Cancer

Kristi Rosa
February 11th 2025
Article

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously treated CCGC.

light blue background with a white outline indicating a clipboard that says FDA

FDA Grants Breakthrough Status to Endometrial Cancer Assay

Kyle Doherty
February 9th 2025
Article

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.